{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:05:10Z","timestamp":1784678710458,"version":"3.55.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100023673","name":"Deanship of Scientific Research, Imam Mohammed Ibn Saud Islamic University","doi-asserted-by":"publisher","award":["IMSIU-DDRSP2501"],"award-info":[{"award-number":["IMSIU-DDRSP2501"]}],"id":[{"id":"10.13039\/501100023673","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Alpha mannosidosis (AM) is a rare lysosomal storage disorder caused by a deficiency in the \u03b1-mannosidase enzyme, resulting in impaired glycoprotein metabolism within lysosomes. Enzyme dysfunction is attributed to an autosomal recessive mutation in the MAN2B1 gene. Affected individuals present with a broad spectrum of manifestations, including developmental delays, cognitive decline, musculoskeletal abnormalities, hearing difficulties, and recurrent infections. Current therapeutic options are limited to hematopoietic stem cell transplantation and the more recently developed enzyme replacement therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The aim of this review was to evaluate and compare the therapeutic outcomes, benefits and challenges associated with Hematopoietic stem cell transplantation (HSCT) and enzyme replacement therapy (ERT) in the treatment of AM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic search across PubMed, MEDLINE, EMBASE, the Cochrane Library, OMIM, and ScienceDirect identified 12 original studies from 307 records. The data are presented narratively due to the scarcity of literature and the heterogeneity of study designs and interventions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 28 patients who received hematopoietic stem cell transplantation showed improvements in preserving neurocognitive function and skeletal stabilization and reduced infection rates, especially when performed at relatively young ages. However, this treatment carries significant risks, including infections, graft-versus-host disease, and increased morbidity and mortality, particularly in older patients. Conversely, enzyme replacement therapy was administered to 75 patients, who demonstrated a favorable safety profile, enhanced respiratory function, reduced skeletal abnormalities, and improved overall quality of life. However, enzyme replacement therapy has limited efficacy in preventing neurocognitive decline and requires lifelong administration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Both interventions yield better outcomes when initiated early, particularly before cognitive deterioration becomes significant. This review emphasizes the importance of a timely diagnosis to optimize treatment outcomes and prevent severe complications.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-026-04394-3","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T23:52:13Z","timestamp":1784677933000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical outcomes in alpha-mannosidosis: a systematic review of therapeutic approaches"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9547-9998","authenticated-orcid":false,"given":"Arezki","family":"Azzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reem Bin","family":"Shlhoob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan","family":"Al-Shehri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,22]]},"reference":[{"issue":"5","key":"4394_CR1","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1542\/peds.2004-0583","volume":"114","author":"PJ Meikle","year":"2004","unstructured":"Meikle PJ, Ranieri E, Simonsen H, et al. Newborn screening for lysosomal storage disorders: clinical evaluation of a two-tier strategy. Pediatrics. 2004;114(5):909\u201316. https:\/\/doi.org\/10.1542\/peds.2004-0583.","journal-title":"Pediatrics"},{"issue":"5","key":"4394_CR2","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1093\/hmg\/6.5.717","volume":"6","author":"O Nilssen","year":"1997","unstructured":"Nilssen O, Berg T, Riise HMF, et al. Alpha-mannosidosis: functional cloning of the lysosomal alpha-mannosidase cDNA and identification of a mutation in two affected siblings. Hum Mol Genet. 1997;6(5):717\u201326. https:\/\/doi.org\/10.1093\/hmg\/6.5.717.","journal-title":"Hum Mol Genet"},{"issue":"5","key":"4394_CR3","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1093\/glycob\/4.5.551","volume":"4","author":"PF Daniel","year":"1994","unstructured":"Daniel PF, Winchester B, Warren CD. Mammalian alpha-mannosidases \u2013 multiple forms but a common purpose? Glycobiology. 1994;4(5):551\u201366. https:\/\/doi.org\/10.1093\/glycob\/4.5.551.","journal-title":"Glycobiology"},{"key":"4394_CR4","first-page":"3507","volume-title":"The Metabolic and Molecular Bases of Inherited Disease","author":"GH Thomas","year":"2001","unstructured":"Thomas GH. Disorders of glycoprotein degradation: alpha-mannosidosis, beta-mannosidosis, fucosidosis, and sialidosis. In: Schriver CR, Beaudet AL, Sly WS, Valle D, editors. The Metabolic and Molecular Bases of Inherited Disease. 8th ed. New York, NY: McGraw-Hill; 2001. pp. 3507\u201333.","edition":"8"},{"key":"4394_CR5","unstructured":"Malm D, Nilssen \u00d8. Alpha-mannosidosis. Orphanet encyclopedia. 2016. Available online: https:\/\/www.orpha.net\/consor\/cgi-bin\/OC_Exp.php?lng=en&Expert=61. Accessed 25 May 2025."},{"key":"4394_CR6","unstructured":"Ficicioglu C, Stepien KM et al. Alpha-Mannosidosis. In: Adam MP, Feldman J, Mirzaa GM, editors. GeneReviews\u00ae [Internet]. Seattle (WA): University of Washington, Seattle; 2001 Oct 11 [updated 2024 Jun 13] [cited 2025 May 22]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1396\/"},{"issue":"4","key":"4394_CR7","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.ymgme.2019.01.024","volume":"126","author":"N Guffon","year":"2019","unstructured":"Guffon N, Tylki-Szymanska A, Borgwardt L, et al. Recognition of alpha-mannosidosis in pediatric and adult patients: presentation of a diagnostic algorithm from an international working group. Mol Genet Metab. 2019;126(4):470\u20134. https:\/\/doi.org\/10.1016\/j.ymgme.2019.01.024.","journal-title":"Mol Genet Metab"},{"key":"4394_CR8","unstructured":"Malm D, Nilssen O, Alpha-Mannosidosis WA. University of Washington, Seattle; 1993\u20132024. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1391\/"},{"key":"4394_CR9","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/1750-1172-3-21","volume":"3","author":"D Malm","year":"2008","unstructured":"Malm D, Nilssen O. Alpha-mannosidosis. Orphanet J Rare Dis. 2008;3:21. https:\/\/doi.org\/10.1186\/1750-1172-3-21.","journal-title":"Orphanet J Rare Dis"},{"issue":"6","key":"4394_CR10","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1002\/humu.22787","volume":"36","author":"HM Riise Stensland","year":"2015","unstructured":"Riise Stensland HM, Frantzen G, Kuokkanen E, Buvang EK, Klenow HB, Heikinheimo P, et al. amamutdb.no: A relational database for MAN2B1 allelic variants that compiles genotypes, clinical phenotypes, and biochemical and structural data of mutant MAN2B1 in \u03b1-mannosidosis. Hum Mutat. 2015;36(6):581\u20136. https:\/\/doi.org\/10.1002\/humu.22787.","journal-title":"Hum Mutat"},{"issue":"10","key":"4394_CR11","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1136\/adc.62.10.1044","volume":"62","author":"A Will","year":"1987","unstructured":"Will A, Cooper A, Hatton C, et al. Bone marrow transplantation in the treatment of alpha-mannosidosis. Arch Dis Child. 1987;62(10):1044\u20139. https:\/\/doi.org\/10.1136\/adc.62.10.1044.","journal-title":"Arch Dis Child"},{"issue":"5","key":"4394_CR12","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.jpeds.2004.01.025","volume":"144","author":"SS Grewal","year":"2004","unstructured":"Grewal SS, Shapiro EG, Krivit W, et al. Effective treatment of alpha-mannosidosis by allogeneic hematopoietic stem cell transplantation. J Pediatr. 2004;144(5):569\u201373. https:\/\/doi.org\/10.1016\/j.jpeds.2004.01.025.","journal-title":"J Pediatr"},{"issue":"3","key":"4394_CR13","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/bmt.2011.99","volume":"47","author":"M Mynarek","year":"2012","unstructured":"Mynarek M, Tolar J, Albert MH, et al. Allogeneic hematopoietic SCT for alpha-mannosidosis: an analysis of 17 patients. Bone Marrow Transpl. 2012;47(3):352\u20139. https:\/\/doi.org\/10.1038\/bmt.2011.99.","journal-title":"Bone Marrow Transpl"},{"issue":"7","key":"4394_CR14","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1111\/j.1399-3046.2012.01763.x","volume":"16","author":"AM Yesilipek","year":"2012","unstructured":"Yesilipek AM, Akcan M, Karasu G, et al. Successful unrelated bone marrow transplantation in two siblings with alpha-mannosidosis. Pediatr Transpl. 2012;16(7):779\u201382. https:\/\/doi.org\/10.1111\/j.1399-3046.2012.01763.x.","journal-title":"Pediatr Transpl"},{"issue":"2","key":"4394_CR15","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/s0022-3476(98)70237-9","volume":"133","author":"DA Wall","year":"1998","unstructured":"Wall DA, Grange DK, Goulding P, et al. Bone marrow transplantation for the treatment of alpha-mannosidosis. J Pediatr. 1998;133(2):282\u20135. https:\/\/doi.org\/10.1016\/s0022-3476(98)70237-9.","journal-title":"J Pediatr"},{"issue":"4","key":"4394_CR16","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/sj.bmt.1704148","volume":"32","author":"MH Albert","year":"2003","unstructured":"Albert MH, Schuster F, Peters C, et al. T-cell-depleted peripheral blood stem cell transplantation for alpha-mannosidosis. Bone Marrow Transpl. 2003;32(4):443\u20136. https:\/\/doi.org\/10.1038\/sj.bmt.1704148.","journal-title":"Bone Marrow Transpl"},{"issue":"Suppl 3","key":"4394_CR17","doi-asserted-by":"publisher","first-page":"S123","DOI":"10.1007\/s10545-009-9035-4","volume":"33","author":"AA Broomfield","year":"2010","unstructured":"Broomfield AA, Chakrapani A, Wraith JE. The effects of early and late bone marrow transplantation in siblings with alpha-mannosidosis: is early hematopoietic cell transplantation the preferred treatment option? J Inherit Metab Dis. 2010;33(Suppl 3):S123\u20137. https:\/\/doi.org\/10.1007\/s10545-009-9035-4.","journal-title":"J Inherit Metab Dis"},{"issue":"7","key":"4394_CR18","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1002\/ajmg.a.63210","volume":"191","author":"L Santoro","year":"2023","unstructured":"Santoro L, Monachesi C, Zampini L, et al. First experience of combined enzyme replacement therapy and hematopoietic stem cell transplantation in alpha-mannosidosis. Am J Med Genet A. 2023;191(7):1948\u201352. https:\/\/doi.org\/10.1002\/ajmg.a.63210.","journal-title":"Am J Med Genet A"},{"key":"4394_CR19","unstructured":"United States Food and Drug Administration. Highlights of prescribing information: LAMZEDE (velmanase alfa-tycv) for injection, for intravenous use. Silver Spring (MD): FDA; 2023 [cited 2025 May 25]. Available from: https:\/\/www.fda.gov\/media\/165488\/download"},{"issue":"4","key":"4394_CR20","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1002\/jimd.12602","volume":"46","author":"N Guffon","year":"2023","unstructured":"Guffon N, Konstantopoulou V, Hennermann JB, et al. Long-term safety and efficacy of velmanase alfa treatment in children under 6 years of age with alpha-mannosidosis: a phase 2, open-label, multicenter study. J Inherit Metab Dis. 2023;46(4):705\u201319. https:\/\/doi.org\/10.1002\/jimd.12602.","journal-title":"J Inherit Metab Dis"},{"issue":"6","key":"4394_CR21","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1007\/s10545-018-0175-2","volume":"41","author":"AM Lund","year":"2018","unstructured":"Lund AM, Borgwardt L, Cattaneo F, et al. Comprehensive long-term efficacy and safety of recombinant human alpha-mannosidase (velmanase alfa) treatment in patients with alpha-mannosidosis. J Inherit Metab Dis. 2018;41(6):1225\u201333. https:\/\/doi.org\/10.1007\/s10545-018-0175-2.","journal-title":"J Inherit Metab Dis"},{"issue":"6","key":"4394_CR22","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1007\/s10545-013-9595-1","volume":"36","author":"L Borgwardt","year":"2013","unstructured":"Borgwardt L, Dali CI, Fogh J, et al. Enzyme replacement therapy for alpha-mannosidosis: 12 months follow-up of a single center, randomized, multiple dose study. J Inherit Metab Dis. 2013;36(6):1015\u201324. https:\/\/doi.org\/10.1007\/s10545-013-9595-1.","journal-title":"J Inherit Metab Dis"},{"issue":"6","key":"4394_CR23","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1007\/s10545-018-0185-0","volume":"41","author":"L Borgwardt","year":"2018","unstructured":"Borgwardt L, Guffon N, Amraoui Y, et al. Efficacy and safety of velmanase alfa in the treatment of patients with alpha-mannosidosis: results from the core and extension phase analysis of a phase III multicenter, double-blind, randomized, placebo-controlled trial. J Inherit Metab Dis. 2018;41(6):1215\u201323. https:\/\/doi.org\/10.1007\/s10545-018-0185-0.","journal-title":"J Inherit Metab Dis"},{"issue":"Suppl","key":"4394_CR24","doi-asserted-by":"publisher","first-page":"S29","DOI":"10.1016\/j.ymgme.2016.11.047","volume":"120","author":"L Borgwardt","year":"2017","unstructured":"Borgwardt L, Lund AM, Amraoui Y, et al. Improvement in fine and gross motor proficiency after long-term enzyme replacement therapy with velmanase alfa (human recombinant alpha-mannosidase) in alpha-mannosidosis patients. Mol Genet Metab. 2017;120(Suppl):S29. https:\/\/doi.org\/10.1016\/j.ymgme.2016.11.047.","journal-title":"Mol Genet Metab"},{"issue":"9","key":"4394_CR25","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1093\/ptj\/89.9.873","volume":"89","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Reprint-preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Phys Ther. 2009;89(9):873\u201380.","journal-title":"Phys Ther"},{"key":"4394_CR26","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan\u2014a web and mobile app for systematic reviews. Syst Rev. 2016;5:210. https:\/\/doi.org\/10.1186\/s13643-016-0384-4.","journal-title":"Syst Rev"},{"key":"4394_CR27","unstructured":"Wells GA, Shea B, O\u2019Connell D et al. The Newcastle\u2013Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. Ottawa Hospital Research Institute. 2013. Available from: http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp. Accessed July 2, 2024."},{"issue":"1","key":"4394_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","volume":"17","author":"AR Jadad","year":"1996","unstructured":"Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17(1):1\u201312. 10.101.","journal-title":"Control Clin Trials"},{"issue":"3","key":"4394_CR29","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1097\/XEB.0000000000000054","volume":"13","author":"Z Munn","year":"2015","unstructured":"Munn Z, Moola S, Lisy K, Riitano D, Tufanaru C. Methodological guidance for systematic reviews of observational epidemiological studies reporting prevalence and incidence data. Int J Evid Based Healthc. 2015;13(3):147\u201353. https:\/\/doi.org\/10.1097\/XEB.0000000000000054.","journal-title":"Int J Evid Based Healthc"},{"issue":"5","key":"4394_CR30","doi-asserted-by":"publisher","first-page":"38","DOI":"10.7453\/gahmj.2013.008","volume":"2","author":"JJ Gagnier","year":"2013","unstructured":"Gagnier JJ, Kienle G, Altman DG, et al. The CARE guidelines: consensus-based clinical case reporting guideline development. Glob Adv Health Med. 2013;2(5):38\u201343. https:\/\/doi.org\/10.7453\/gahmj.2013.008.","journal-title":"Glob Adv Health Med"},{"key":"4394_CR31","doi-asserted-by":"publisher","first-page":"100480","DOI":"10.1016\/j.ymgmr.2019.100480","volume":"20","author":"J Adam","year":"2019","unstructured":"Adam J, Malone R, Lloyd S, Lee J, Hendriksz CJ, Ramaswami U. Disease progression of alpha-mannosidosis and impact on patients and carers\u2014A UK natural history survey. Mol Genet Metab Rep. 2019;20:100480. https:\/\/doi.org\/10.1016\/j.ymgmr.2019.100480.","journal-title":"Mol Genet Metab Rep"},{"key":"4394_CR32","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/1750-1172-8-88","volume":"8","author":"M Beck","year":"2013","unstructured":"Beck M, Olsen KJ, Wraith JE, et al. Natural history of alpha mannosidosis: a longitudinal study. Orphanet J Rare Dis. 2013;8:88. https:\/\/doi.org\/10.1186\/1750-1172-8-88.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"4394_CR33","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s10545-013-9648-5","volume":"37","author":"D Malm","year":"2014","unstructured":"Malm D, Nilssen \u00d8, Tollersrud OK, et al. The natural course and complications of alpha-mannosidosis: a retrospective and descriptive study. J Inherit Metab Dis. 2014;37(1):79\u201382. https:\/\/doi.org\/10.1007\/s10545-013-9648-5.","journal-title":"J Inherit Metab Dis"},{"issue":"4","key":"4394_CR34","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.bbmt.2005.12.026","volume":"12","author":"S Kharbanda","year":"2006","unstructured":"Kharbanda S, Panoskaltsis-Mortari A, Haddad IY, et al. Inflammatory cytokines and the development of pulmonary complications after allogeneic hematopoietic cell transplantation with inherited metabolic storage disorders. Biol Blood Marrow Transpl. 2006;12(4):430\u20137. https:\/\/doi.org\/10.1016\/j.bbmt.2005.12.026.","journal-title":"Biol Blood Marrow Transpl"},{"key":"4394_CR35","unstructured":"European Medicines Agency, Lamzede. velmanase alfa. 2018. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/lamzede. Accessed July 11, 2024."},{"key":"4394_CR36","doi-asserted-by":"publisher","first-page":"100586","DOI":"10.1016\/j.ymgmr.2020.100586","volume":"23","author":"D Phillips","year":"2020","unstructured":"Phillips D, Hennermann JB, Tylki-Szymanska A, et al. Use of the Bruininks-Oseretsky test of motor proficiency (BOT-2) to assess efficacy of velmanase alfa as enzyme therapy for alpha-mannosidosis. Mol Genet Metab Rep. 2020;23:100586. https:\/\/doi.org\/10.1016\/j.ymgmr.2020.100586.","journal-title":"Mol Genet Metab Rep"},{"issue":"1","key":"4394_CR37","doi-asserted-by":"publisher","first-page":"e12799","DOI":"10.1002\/jimd.12799","volume":"48","author":"N Guffon","year":"2025","unstructured":"Guffon N, Borgwardt L, Tylki-Szyma\u0144ska A, Ballabeni A, Don\u00e0 F, Joseph A, et al. Extended long-term efficacy and safety of velmanase alfa treatment up to 12 years in patients with alpha-mannosidosis. J Inherit Metab Dis. 2025;48(1):e12799. https:\/\/doi.org\/10.1002\/jimd.12799.","journal-title":"J Inherit Metab Dis"},{"key":"4394_CR38","doi-asserted-by":"publisher","first-page":"S30","DOI":"10.1016\/j.ymgme.2016.11.048","volume":"120","author":"L Borgwardt","year":"2017","unstructured":"Borgwardt L, Lund AM, Amraoui Y, et al. Long-term enzyme replacement therapy with velmanase alfa (human recombinant alpha-mannosidase) slows disease progression in adult patients suffering from alpha-mannosidosis. Mol Genet Metab. 2017;120:S30. https:\/\/doi.org\/10.1016\/j.ymgme.2016.11.048.","journal-title":"Mol Genet Metab"},{"issue":"2","key":"4394_CR39","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1002\/jmd2.12349","volume":"64","author":"LG Borgwardt","year":"2022","unstructured":"Borgwardt LG, Ceravolo F, Zardi G, et al. Relationship between MAN2B1 genotype\/subcellular localization subgroups, antidrug antibody detection, and long-term velmanase alfa treatment outcomes in patients with alpha-mannosidosis. JIMD Rep. 2022;64(2):187\u201398. https:\/\/doi.org\/10.1002\/jmd2.12349.","journal-title":"JIMD Rep"},{"issue":"Suppl 1","key":"4394_CR40","first-page":"185","volume":"12","author":"L Borgwardt","year":"2014","unstructured":"Borgwardt L, Lund AM, Dali CI. Alpha-mannosidosis: a review of genetic, clinical findings and options of treatment. Pediatr Endocrinol Rev. 2014;12(Suppl 1):185\u201391.","journal-title":"Pediatr Endocrinol Rev"},{"issue":"1","key":"4394_CR41","doi-asserted-by":"publisher","first-page":"108444","DOI":"10.1016\/j.ymgme.2024.108444","volume":"142","author":"L Santoro","year":"2024","unstructured":"Santoro L, Cefalo G, Canalini F, Rossi S, Scarpa M. Diagnosis of alpha-Mannosidosis: Practical approaches to reducing diagnostic delays in this ultrarare disease. Mol Genet Metab. 2024;142(1):108444. https:\/\/doi.org\/10.1016\/j.ymgme.2024.108444.","journal-title":"Mol Genet Metab"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04394-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-026-04394-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04394-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T23:52:15Z","timestamp":1784677935000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13023-026-04394-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,22]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4394"],"URL":"https:\/\/doi.org\/10.1186\/s13023-026-04394-3","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,22]]},"assertion":[{"value":"18 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"255"}}